Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded GLP-1s—medications containing the same active ingredients as the blockbuster weight-loss drugs but sold at a much lower price.
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.
Who can get weight loss drugs on the NHS in Scotland?
The medicines watchdog has agreed the drugs are safe and cost-effective for NHS use. Last year, semaglutide was approved for treating obesity under the brand name Wegovy. It has also been licensed under the brand name Ozempic for treating diabetes in some circumstances,
Compound versions of weight loss drugs will no longer be available, FDA rules
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.
Medications For Weight Loss
Dr. Alexandro Zarruk, MD, MSc., FACP, FRCPC, Internal Medicine, talks about medications that can help patients lose weight.
Fierce Pharma3d
Neurotech nabs FDA approval to treat rare eye disorder with cell therapy implant Encelto
With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...
Medscape2d
Compounders Face Deadline to Stop Manufacturing Tirzepatide
The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...
Ophthalmology Times7d
FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2
Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.
PharmExec7d
FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients
The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...
MPR3d
FDA to Review Depemokimab for Asthma With Eosinophilic Phenotype, CRSwNP
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Nasdaq3d
Biodexa Pharmaceuticals PLC Achieves Key Milestone with FDA Following Type C Meeting for Phase 3 eRapa Study in Familial Adenomatous Polyposis
Biodexa Pharmaceuticals announced a successful Type C meeting with the FDA, which has cleared the way to finalize the Phase 3 protocol for its drug eRapa in treating familial adenomatous polyposis ...
Healio7d
FDA approves epinephrine nasal spray for children aged as young as 4 years
The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...
Telegram10d
A recall on granola bars has been updated. Here's what to know about it
The FDA just announced the recall has been updated to a "Class II" incident. The FDA issues a Class II recall when a product has a low risk of doing harm, but still has a chance to cause adverse ...
MPR7d
FDA Approves Encelto for Macular Telangiectasia Type 2
MacTel is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.